

Refractory Epilepsy- Pipeline Insight, 2019

<https://marketpublishers.com/r/R05C5960CE3EN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: R05C5960CE3EN

Abstracts

This report can be delivered to the clients within 24 Hours

"Refractory Epilepsy- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Refractory Epilepsy pipeline landscape is provided which includes the disease overview and Refractory Epilepsy treatment guidelines. The assessment part of the report embraces, in depth Refractory Epilepsy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Epilepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Refractory Epilepsy Understanding

Patients with epilepsy whose seizures do not successfully respond to anti-seizure drug therapy are considered to have Refractory Epilepsy. This condition is also referred to as intractable, drug-resistant, or pharmaco-resistant epilepsy. Refractory or uncontrolled epilepsy is a heavy burden. According to Epilepsy Foundation, in the United States, approximately 3.4 million people live with epilepsy, and over 150,000 new cases are diagnosed each year. One in 26 people will develop epilepsy at some point in their life. Epilepsy doesn't discriminate. It affects children and adults, men and women, and people of all races, religions, ethnic backgrounds, and social classes. While epilepsy is most often diagnosed either in childhood or after the age of 65, it can occur at any age. The common triggers of epilepsy include Sleep deprivation, overtired, not sleeping well, not getting enough sleep, flashing bright lights or patterns, alcohol consumption, stress, low blood sugar, etc.

Refractory Epilepsy Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Refractory Epilepsy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Refractory Epilepsy pipeline report covers 8+ companies. Some of the key players include UCB Biopharma (Padsevoniil (UCB0942)), Aquestive Therapeutics (AQST-203), PTC Therapeutics (Ataluren) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Refractory Epilepsy Analytical Perspective by DelveInsight

In-depth Refractory Epilepsy Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Refractory Epilepsy Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Refractory Epilepsy report provides an overview of therapeutic pipeline activity for Refractory Epilepsy across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Refractory Epilepsy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Refractory Epilepsy Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Refractory Epilepsy

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Refractory Epilepsy to formulate effective R&D strategies

Assess challenges and opportunities that influence Refractory Epilepsy R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially

lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Refractory Epilepsy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Refractory Epilepsy to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the

reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. REFRACTORY EPILEPSY

- 2.1. Refractory Epilepsy Disease Overview
- 2.2. Refractory Epilepsy History
- 2.3. Refractory Epilepsy Symptoms
- 2.4. Refractory Epilepsy Causes
- 2.5. Refractory Epilepsy Pathophysiology
- 2.6. Refractory Epilepsy Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. REFRACTORY EPILEPSY CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. REFRACTORY EPILEPSY - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Refractory Epilepsy companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Refractory Epilepsy Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Refractory Epilepsy Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. REFRACTORY EPILEPSY PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. REFRACTORY EPILEPSY-PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. Padsevonil (UCB0942)- UCB Biopharma
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
 - 6.1.2. AQST-203- Aquestive Therapeutics
 - 6.1.2.1. Product Description
 - 6.1.2.1.1. Product Overview
 - 6.1.2.1.2. Mechanism of Action
 - 6.1.2.2. Research and Development
 - 6.1.2.2.1. Clinical Studies
 - 6.1.2.2.1.1. Detailed Study Description
 - 6.1.2.2.1.2. Study Results
 - 6.1.2.2.1.3. Clinical Trials: Tabular View
 - 6.1.2.3. Product Development Activities
 - 6.1.2.3.1. Tabulated Product Summary
 - 6.1.2.3.1.1. General Description Table
 - 6.1.3. Ataluren- PTC Therapeutics

- 6.1.3.1. Product Description
 - 6.1.3.1.1. Product Overview
 - 6.1.3.1.2. Mechanism of Action
- 6.1.3.2. Research and Development
 - 6.1.3.2.1. Clinical Studies
 - 6.1.3.2.1.1. Detailed Study Description
 - 6.1.3.2.1.2. Study Results
 - 6.1.3.2.1.3. Clinical Trials: Tabular View
- 6.1.3.3. Product Development Activities
 - 6.1.3.3.1. Tabulated Product Summary
 - 6.1.3.3.1.1. General Description Table

To be continued in the report.....

7. RECENT TECHNOLOGIES

8. REFRACTORY EPILEPSY KEY COMPANIES

- 8.1. UCB Pharma
- 8.2. Bial
- 8.3. Threshold Pharmaceuticals
- 8.4. Aquestive Therapeutics
- 8.5. Eisai
- 8.6. Marinus Pharmaceuticals
- 8.7. GW Pharmaceuticals
- 8.8. PTC Therapeutics
- 8.9. UCB Pharma

9. REFRACTORY EPILEPSY KEY PRODUCTS

- 9.1. Padsevonil
- 9.2. Seletacetam
- 9.3. Eslicarbazepine acetate
- 9.4. AQST-203
- 9.5. 2-Deoxy-D-glucose
- 9.6. Perampanel
- 9.7. Ganaxolone
- 9.8. Cannabidiol
- 9.9. Ataluren

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. REFRACTORY EPILEPSY - UNMET NEEDS

12. REFRACTORY EPILEPSY - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research

14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Refractory Epilepsy Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Refractory Epilepsy Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Refractory Epilepsy companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Refractory Epilepsy Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

UCB Pharma
Bial
Threshold Pharmaceuticals
Pfizer

Biocodex

Eisai

Marinus Pharmaceuticals

GW Pharmaceuticals

Eisai Co Ltd

I would like to order

Product name: Refractory Epilepsy- Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/R05C5960CE3EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R05C5960CE3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970